Catalent (NYSE:CTLT) Downgraded by StockNews.com to “Sell”

Catalent (NYSE:CTLT) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a report issued on Wednesday.

CTLT has been the topic of a number of other reports. Royal Bank of Canada reiterated a “sector perform” rating and issued a $63.50 price objective on shares of Catalent in a report on Thursday, July 11th. Baird R W lowered Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. William Blair reissued a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Finally, Robert W. Baird reaffirmed a “neutral” rating and issued a $63.50 target price on shares of Catalent in a research report on Tuesday, September 24th. One equities research analyst has rated the stock with a sell rating and eight have assigned a hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $59.83.

Catalent Stock Performance

Shares of Catalent stock opened at $59.89 on Wednesday. The business’s 50 day moving average price is $60.01 and its 200 day moving average price is $58.05. The company has a market cap of $10.87 billion, a price-to-earnings ratio of -10.91, a PEG ratio of 2.06 and a beta of 1.16. The company has a debt-to-equity ratio of 1.35, a quick ratio of 1.96 and a current ratio of 2.52. Catalent has a one year low of $32.38 and a one year high of $61.20.

Catalent (NYSE:CTLT) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.18). The company had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.06 billion. Catalent had a negative return on equity of 0.56% and a negative net margin of 22.72%. The firm’s revenue was up 4.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.10) EPS. On average, research analysts predict that Catalent will post 0.95 EPS for the current year.

Insider Buying and Selling

In other Catalent news, insider David Mcerlane sold 1,994 shares of the firm’s stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the transaction, the insider now owns 36,304 shares of the company’s stock, valued at $2,177,150.88. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 0.31% of the stock is owned by insiders.

Institutional Investors Weigh In On Catalent

A number of hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its position in shares of Catalent by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 20,405,181 shares of the company’s stock worth $1,151,872,000 after buying an additional 218,682 shares during the last quarter. Millennium Management LLC boosted its stake in Catalent by 129.2% in the second quarter. Millennium Management LLC now owns 4,079,964 shares of the company’s stock valued at $229,416,000 after acquiring an additional 2,299,784 shares in the last quarter. Alpine Associates Management Inc. grew its holdings in shares of Catalent by 3.8% during the second quarter. Alpine Associates Management Inc. now owns 2,061,251 shares of the company’s stock worth $115,904,000 after purchasing an additional 75,700 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Catalent by 14.9% during the second quarter. Bank of New York Mellon Corp now owns 1,930,621 shares of the company’s stock worth $108,559,000 after purchasing an additional 250,999 shares in the last quarter. Finally, Marshall Wace LLP lifted its holdings in shares of Catalent by 5.1% in the 2nd quarter. Marshall Wace LLP now owns 1,792,951 shares of the company’s stock valued at $100,818,000 after purchasing an additional 86,533 shares during the last quarter.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.